Ocugen Investoren 2022 WKN: A2PSZH ISIN: US67577C1053 Forum: Aktien User: Ad_Astra

COVAXIN Booster Dose 💉💉💉 1⃣3rd dose leads 5X antibodies 🆚 2 dose 2⃣3rd Dose neutralising all variants (Omicron results 🔜) 3⃣Increase in Breadth & Depth of Immune responses 3⃣No safety concerns/favourable risk-benefit profile 4⃣Long term T&B cell responses after 2 doses.

Covaxin Booster Dose Safe and Highly Immunogenic (against all variants) #covaxin #BharatBiotech #COVID19Vaccine #COVID19 #boosterdose #SARS_CoV_2

https://twitter.com/bharatbiotech/status/1479800788335542273?s=21

Booster

https://twitter.com/BharatBiotech/status/1479800788335542273?s=20

https://twitter.com/bharatbiotech/status/1479797790041513984?s=21

Sean Lee -- Citi -- Analyst My first one is on the supply agreement with Bharat. So does that cover a potential commercial supply, if you're EUA for the pediatric population is approved? How much supply would you have access to and also in terms of the tech transfer to Jubilant? What's the progress on and the expected timeline on that? Shankar Musunuri -- Chairman and Chief Executive Officer Yes, upon EUA, our supply agreement does include adequate doses, Sean, and our partners have significantly increased that capacity this year. And also so that they don't how many restrictions for export. So we will be -- we'll get adequate supply whatever is needed post EUA in the US. And as for as technology transfer is concerned at Jubilant HollisterStier, the program is going well and we are anticipating completion of establishing that including process validations in the first half of next year. So that, we can switch the supply and so the initial part of the supply does include -- even we did see a product from biotech our partners it will include US packaging and the testing from the US release site, which have been established. Sean Lee -- Citi -- Analyst Once the tech transfer is completed next year, would you need additional CMC validation from the FDA to show that the clinical batch and the commercial batch of the same? Shankar Musunuri -- Chairman and Chief Executive Officer Yeah. That's a normal part of the process when you add an additional site, you always have to show the compatibility and that would be the product process.

Neverending Story

SpiegelOnline: 7.36 Uhr: Die Bundesregierung will angesichts drohender weiterer Corona-Wellen die raschere Entwicklung von Impfstoffen ermöglichen. »Wenn wir eine Variante bekommen, die so ansteckend ist wie Omikron, aber deutlich tödlicher, müssten wir in allerkürzester Zeit in der Lage sein, einen neuen Impfstoff zu entwickeln und zu produzieren«, sagte Bundesgesundheitsminister Karl Lauterbach (SPD) der »Welt am Sonntag«. Darauf bereite sich die Bundesregierung »mit Hochdruck« vor.